BNR

Burning Rock Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.96
-0.50
-2.33%
After Hours: 20.96 0 0.00% 16:00 08/14 EDT
OPEN
21.42
PREV CLOSE
21.46
HIGH
21.48
LOW
20.80
VOLUME
114.67K
TURNOVER
--
52 WEEK HIGH
32.40
52 WEEK LOW
20.51
MARKET CAP
2.14B
P/E (TTM)
-43.7396
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BNR stock price target is 31.45 with a high estimate of 31.90 and a low estimate of 31.00.

EPS

BNR News

More
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 2d ago
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 3d ago
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 4d ago
Burning Rock Schedules Second Quarter of 2020 Earnings Release on August 11, 2020
GUANGZHOU, China, July 20, 2020 -- Burning Rock Biotech Limited (NASDAQ: BNR) today announced that it plans to release its unaudited financial results for the second quarter of.
GlobeNewswire · 07/21 01:52
Burning Rock Biotech shares are trading higher amid expiration of the company's IPO quiet period expiring later this week.
Benzinga · 07/06 13:01
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. 
Benzinga · 07/06 12:56
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
GlobeNewswire · 06/29 02:00
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26

Industry

Healthcare Facilities & Services
+0.57%
Healthcare Providers & Services
+0.63%

Hot Stocks

Symbol
Price
%Change

About BNR

Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
More

Webull offers kinds of Burning Rock Biotech Ltd(ADR) stock information, including NASDAQ:BNR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNR stock methods without spending real money on the virtual paper trading platform.